Phaseline

Targets › MGAT5

MGAT5 (Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jul 2027.

Catalyzes the addition of N-acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary N-linked oligosaccharides. Catalyzes an important step in the biosynthesis of branched, complex-type N-glycans, such as those found on EGFR, TGFR (TGF-beta receptor) and CDH2. (UniProt, Q09328)

Open in Phaseline: the race on MGAT5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Phost'In TherapeuticsPhOx430
Acetylglucosaminyltransferase V inhibitor
MGAT5Phase 1Malignant TumorJul 2027

Conditions

Malignant Tumor (1)

Modalities

protein or peptide (1)

Companies

Phost'In Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.